eli lilly glp-1 drugs Novo, weight-loss should be first option obesity treatments, European doctors say Study flags need to monitor

[DOI] [PubMed] [Google Scholar] 218.Seifarth C., Bergmann J., Holst J.J., Ritzel R., Schmiegel W., Nauck M.A

Some researchers have highlighted post-treatment study findings that have shown that people tend to suffer from a high risk of weight regain after stopping these drugs

19 The GLP-1 receptor agonists will also amplify the insulin signaling in the cells of the brain, which will increase insulin sensitivity in the neurons

Likely impacts of recruitment site and methodology on characteristics of enrolled patient population: irritable bowel syndrome clinical trial design

GLP-1 RAs also have a series of beneficial multifactorial effects beyond glycaemic control that include reduction of body weight and improvement of cardiovascular (CV) outcomes [14]